Let’s clarify what decentralized clinical trials are before this bubble bursts!
In this episode, Hassan Kadhim, global head of clinical trial business capabilities at Bristol-Myers Squibb, takes a very sober look at decentralized clinical trials: what they mean to him, how they are evolving, and why they are here to stay. To incentivize progress around DCTs, Bristol-Myers Squibb came up with a definition for the term “decentralized clinical trial” that enlists four traditional capabilities and four up-and-coming ones, all of which Hassan explains. He discusses the design and coordination for the implementation of DCTs to collect the necessary patient data in a comfortable burdenless manner. Not all countries, organizations, or sites are ready to implement DCTs; Hassan thinks ever since COVID, the industry has changed in that way.
Tune in to this episode to hear more about DCTs from Hassan and learn where they’re taking the research industry!
Click this link to the show notes, transcript, and resources: outcomesrocket.health
Outcomes Rocket